Skip to content

Presidential Plenary: The Future of Expanded Newborn Genomic Screening

ACMG 2026's opening plenary frames the policy + clinical-lab debate over moving newborn screening from biochemical panels to whole-genome sequencing — with the cancer-predisposition reporting wedge as a load-bearing sub-question.

  • Speaker / institution: Presidential Plenary panel (ACMG leadership + BabySeq2 / GUARDIAN / NBSeq / EarlyCheck program PIs); combined with ACMG Foundation Awards ceremony and Rimoin Lecture
  • Anchor type: guideline + cohort
  • Day / session: Day 2 (Wed Mar 11, 2026) — Presidential Plenary, morning, Baltimore Convention Center
  • Status: post-meeting; from ACMG meeting site + PRNewswire pre-meeting press; per-talk speaker slate and concrete recommendations TBD pending GIM abstract supplement and Digital Edition recordings

Headline finding

The plenary is the field's coordinating moment on how, when, and with what consent framework the four major US newborn-genomic-screening pilots (BabySeq2, GUARDIAN at Columbia, NBSeq, EarlyCheck) translate into a generalizable clinical-lab service. Specific cohort numerics (cumulative consented infants, additional-condition yield, false-positive rates per disorder, return-of-results uptake) TBD pending GIM supplement. The cancer-predisposition reporting wedge — whether RB1, TP53, RET, APC, BRCA1/2, MLH1, MSH2, MSH6, PMS2 variants should be reported from newborn WGS, and to whom — is treated as a discrete policy axis.

Methodology / framework

Panel format combining cohort readouts (BabySeq2 randomized return-of-results trial; GUARDIAN's >100k-infant screening pilot; NBSeq; EarlyCheck) with framework discussion of the ACMG/AMP variant-classification thresholds appropriate for asymptomatic newborns, the role of the ACMG Secondary Findings v3.3 list, and gene-list selection (actionable pediatric-onset only, vs adult-onset cancer-predisposition genes reported deferred-to-adulthood vs reported-to-parents).

Lab-translation deep dive

Validation requirements. Moving newborn screening from biochemical panels to WGS requires net-new CLIA/CAP validation packages for every step the pilots formalized as research-grade: maternal-blood / heel-stick DNA extraction reproducibility at neonatal volumes, library-prep performance on low-input gDNA, WGS coverage uniformity across the actionable gene list (≥20x median, ≥10x at >99% of targeted bases as a working floor — formal NBS-WGS minimums TBD pending plenary recommendations), and bioinformatics-pipeline validation against a contrived NBS truth set. The four pilots (BabySeq2, GUARDIAN, NBSeq, EarlyCheck) used overlapping but non-identical gene lists, which is itself a validation-portability problem.

Lab-stack changes. Existing biochemical NBS labs (state public-health labs) are not configured for clinical WGS turnaround; the plenary's translation question is whether NBS-WGS sits in (a) the existing state-public-health lab footprint with new sequencer capex, (b) a centralized reference-lab model (akin to current expanded carrier screening), or (c) hybrid biochemical-first / WGS-reflex. TAT expectations (current biochemical NBS: 5–7 days from heel stick) are a hard constraint that shapes the answer.

Regulatory / insurance. No CMS coverage policy for routine newborn WGS as of 2026; state Medicaid coverage is patchwork. FDA's stance on NBS-WGS as a screening (not diagnostic) modality is unresolved. ACMG SF v3.3 interaction is the load-bearing payer question.

Variant curation. Requires ClinGen-VCEP-aware automated triage at NBS scale (millions of births/year if universal). Manual sign-out per infant is not operationally viable; the workflow must be variant-prefiltered, with human review only for borderline P/LP and any reportable SF variant. Specific automation thresholds TBD pending plenary.

Where it fits in the corpus

  • AACR 2026: Pediatric Cancer Predisposition Working Group sessions (Apr 17–22, Chicago) — same gene set, downstream of newborn-WGS reporting decisions
  • ASHG 2026 / ESHG 2026: sibling NBS-genomics methods talks; see acmg-sf-v33-secondary-findings.md
  • ASCO 2026: Lynch / HBOC surveillance trial-eligibility pathways inherit from how NBS-era variants are returned

Open questions

  • Should adult-onset cancer-predisposition variants be reported from newborn WGS at all, and if so to parents or held to age 18?
  • How does newborn WGS interact with the ACMG SF v3.3 list — is SF a floor, ceiling, or orthogonal?
  • Payer coverage trajectory for newborn WGS in 2026–2028 — state-by-state vs federal

Sources